论文部分内容阅读
目的:观察玻连蛋白(vitronectin,VTN)在前列腺癌组织及患者血清中的表达,并探讨其临床意义及与前列腺癌转移的相关性。方法:应用免疫组织化学法检测2010-01-01-2012-12-31新疆医科大学附属肿瘤医院泌尿外科34例前列腺癌转移(prostate cancer metastasis,PCaM)患者、32例前列腺癌未转移(prostate cancer,PCa)患者及29例良性前列腺增生(benign prostatic hyperplasia,BPH)患者组织中VTN表达,通过χ2检验比较各组组织中VTN的表达差异,分析前列腺癌组织中VTN表达与临床病理因素的相关性;同时用蛋白印迹法检测相应患者血清中VTN表达,通过方差分析及SNK法检验各组血清中VTN的表达差异。结果:BPH组、PCa组及PCaM组组织样本中VTN的阳性表达率分别为82.76%(24/29)、59.38%(19/32)及32.35%(11/34),VTN在BPH组组织中的表达水平高于PCa组,PCa组高于PCaM组,χ2=16.34,P<0.001;前列腺癌组织中VTN表达与患者初诊血清PSA(P=0.004)、肿瘤临床分期(P=0.025)及Gleason评分(P=0.004)存在相关性;VTN在BPH组血清样本中的光密度比值为0.83±0.07,高于PCa组0.65±0.06,PCa组高于PCaM组0.35±0.08,P<0.001。结论:VTN与前列腺癌的发生和转移可能相关,并可能在前列腺癌的进展中起重要作用,借助测定血清VTN的表达可能可以协助前列腺癌的诊断和疾病进展评估。
OBJECTIVE: To investigate the expression of vitronectin (VTN) in serum of patients with prostate cancer and its clinical significance and its correlation with the metastasis of prostate cancer. Methods: Immunohistochemical method was used to detect 34 cases of prostate cancer metastasis (PCaM) in Department of Urology, Cancer Hospital Affiliated to Xinjiang Medical University, 2010-01-01-2012-12-31. 32 cases of prostate cancer without metastasis , PCa) and 29 patients with benign prostatic hyperplasia (BPH). The expression of VTN in each group was compared by χ2 test, and the correlation between the expression of VTN and clinicopathological factors was analyzed At the same time, the expression of VTN in sera of the corresponding patients was detected by Western blotting. The difference of the expression of VTN in each group was tested by analysis of variance and SNK method. Results: The positive rates of VTN in BPH group, PCa group and PCaM group were 82.76% (24/29), 59.38% (19/32) and 32.35% (11/34), respectively. The expression of VTN in BPH group (P = 0.004), the clinical stage of tumor (P = 0.025) and the level of Gleason in PCa group were higher than that in PCaM group (χ2 = 16.34, P <0.001) (P = 0.004). The optical density ratio of VTN in BPH serum samples was 0.83 ± 0.07, higher than that in PCa group (0.65 ± 0.06), PCa group (0.35 ± 0.08, P <0.001) in PCaM group. CONCLUSION: VTN may be related to the occurrence and metastasis of prostate cancer and may play an important role in the progression of prostate cancer. The determination of serum VTN may be helpful for the diagnosis of prostate cancer and assessment of disease progression.